trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['congrat', 'osel']
 congrats . will be so important to understand the real-world experience of t-dxd ild in more vulnerable pts w/ greater comorbidities that are less closely monitored &amp; managed &amp; understand biology &amp;risk factors for more serious outcomes #asco22 
Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine.